Celcuity CEO to Present at Key Healthcare Investor Conferences
Event summary
- Celcuity CEO Brian Sullivan to present at Jefferies Global Healthcare Conference on June 4, 2026.
- Sullivan also scheduled for Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026.
- Live webcasts available for both events via company's investor relations page.
- Celcuity's lead therapeutic candidate is gedatolisib, targeting PI3K/AKT/mTOR pathway.
- Phase 3 VIKTORIA-1 trial reported detailed results for PIK3CA WT tumors and topline results for PIK3CA MT tumors.
The big picture
Celcuity's participation in high-profile investor conferences comes at a critical juncture as it seeks to advance its lead therapeutic candidate, gedatolisib, through late-stage clinical trials. The company's focus on targeted therapies for solid tumors positions it within a competitive but growing segment of oncology innovation. Success in these trials and effective investor outreach could significantly enhance its market valuation and strategic partnerships.
What we're watching
- Clinical Trial Progress
- How the detailed results from VIKTORIA-1 Study 1 and topline results from Study 2 will impact investor sentiment and potential partnerships.
- Investor Engagement
- Whether Celcuity can leverage these conferences to attract new investors or strategic collaborators for its lead candidate gedatolisib.
- Market Positioning
- The pace at which Celcuity can differentiate gedatolisib in a competitive landscape of PI3K/AKT/mTOR pathway inhibitors.
Related topics